Slingshot members are tracking this event:

Pfizer's (PFE) Prevenar Approved in China for the Prevention of Invasive Pneumococcal Disease in Infants and Children Aged Six Weeks to Fifteen Months

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details In China, the recommended Prevenar 13® immunization series is a primary series administered at 2, 4 and 6 months of age with a fourth (booster) dose administered at approximately 12~15 months of age.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Prevenar, China, Prevention, Invasive Pneumococcal Disease, Infants, Children, Six Weeks To Fifteen Months